MeSH tree: D08.811.277.656
Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature within tumors that can help identify patients with metastatic castration-resistant ...
May 21, 2026
0
5
A B.C.-led clinical research team is behind a study that could help improve care for critically ill patients in intensive care units worldwide. Researchers from Royal Columbian Hospital and Simon Fraser University have published ...
May 19, 2026
0
1
Chemotherapy can be life-saving for many patients, but not all tumors respond—and some that do, may eventually become resistant. Investigators at Houston Methodist have identified a possible explanation for this resistance, ...
May 18, 2026
0
6
A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than current tests, according to a U.K.-wide study led by UCL researchers. The study, published in Nature ...
May 18, 2026
0
22
Thomas Delong, Ph.D., moved to Colorado from Germany two decades ago intent on one thing: understanding the origin of type 1 diabetes (T1D) and finding ways to stop it. Diagnosed at age 12 with the disease that affects 9.5 ...
May 18, 2026
0
7
Most men with low-grade prostate cancer have an excellent prognosis, with a five-year survival rate of more than 99%. But radical prostatectomy—surgery to remove the prostate—can lead to sexual and physical dysfunction, fatigue, ...
May 11, 2026
0
6
A large analysis of two major clinical trials has found that the spread of prostate cancer can be detected on imaging scans even when biomarkers remain stable in patients treated with androgen receptor inhibitors, according ...
Apr 27, 2026
0
10
Injections of botulinum toxin, commonly known as Botox, could be an effective and well-tolerated option for treating debilitating complications caused by reduced blood flow to the fingers, such as acute digital ischemia (which ...
Mar 20, 2026
0
7
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own immune arsenal to fight ...
Mar 19, 2026
0
7
A clotbusting drug commonly used to treat ischemic stroke interacts negatively with a promising anti-inflammatory treatment (anakinra), underscoring the need to test new stroke therapies alongside existing standard care. ...
Mar 19, 2026
0
4
